By improving detection of atrial fibrillation, more affected individuals can provide researchers with valuable information and a potential signal to treat, said Brent A. Williams, PhD, research investigator focusing on the optimal incorporation of cardiac imaging technologies in clinical practice for Geisinger.
By improving detection of atrial fibrillation, more affected individuals can provide researchers with valuable information and a potential signal to treat, said Brent A. Williams, PhD, research investigator focusing on the optimal incorporation of cardiac imaging technologies in clinical practice for Geisinger.
Transcript
Based on the study results from your session, “Explaining Temporal Trends in Atrial Fibrillation Incidence Rates,” presented at this year’s American Heart Association meeting, what progressions in preventive atrial fibrillation detection were found and what underlying factors remained unmonitored?
A lot of what we noticed in our study, was that the population at risk for atrial fibrillation—so, this group doesn't have any atrial fibrillation yet, but could develop it in the near term–that group of patients are getting heavier; their BM is above 30, the prevalence of that is increasing over time, they're more likely to have hypertension over time. Of course, high BMI and hypertension are 2 of the most common risk factors for atrial fibrillation. So, I think the increasing incidence we saw was largely a combination of the at-risk population having more risk factors, and also more opportunity to diagnose atrial fibrillation. We noticed that there was a sharp increase in least documentation of short-term ECG, 1-time ECG in our at-risk population. More and more atrial fibrillation is being diagnosed via implanted devices like pacemakers and implantable cardioverter defibrillators. So, I think those 2 things in particular are kind of working collectively that we're finding more atrial fibrillation–not that this is necessarily a bad thing. You see that line of new afib [atrial fibrillation] cases going up and it looks bad, but I think we're uncovering what's already there, which can give us a signal to treat.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More